
Long-term clinical trial results for Hanmi Pharmaceutical's first domestically produced GLP-1 (glucagon-like peptide-1) class obesity drug, 'Epe' (active ingredient: epeglenatide), in Korean patients have been released. The average weight loss rate after 64 weeks of administration was 10.56%, which is 0.81 percentage points higher than the previous 40-week interim result (9.75%).
According to the pharmaceutical industry on the 18th, Hanmi Pharmaceutical disclosed the 64th-week results of the domestic Phase 3 clinical trial for epeglenatide at the 'American Association of Clinical Endocrinology' on the 16th (local time). The study was conducted on 448 adults with obesity or overweight in Korea. It was designed primarily around the body mass index (BMI) range of 27 to 35 kg/m², reflecting Korean obesity criteria and actual patient distribution. Approximately 30% of clinical trial participants had a BMI below 30 kg/m², while approximately 52% had a BMI of 30 kg/m² or higher but less than 35 kg/m², meaning that about 82% of the total had a BMI below 35 kg/m².
Clinical results showed that the average weight loss rate was 9.75% with gradual dose escalation of Epe over 40 weeks, and 10.56% with administration over 64 weeks.
This is slightly lower than the record at week 68 for Novo's GLP-1 class obesity drug 'Wegovy' (active ingredient: semaglutide). Wegovy recorded an average weight loss rate of 13.2% at 68 weeks in the Phase 3a clinical trial 'STEP 6' conducted in Korea and Japan. This was the result for the 2.4 mg dosing group, while the 1.7 mg dosing group showed a weight loss rate of 9.6%, and the placebo group showed a weight loss rate of 2.1%.
Epe underwent clinical trials on Korean patients without diabetes. Wegovy conducted the trial in STEP 6 in Korea and Japan, including some patients with diabetes. In 'STEP 1,' a global clinical trial targeting populations such as Western countries with a high proportion of severe obesity patients, Wegovy's average weight loss rate at 68 weeks with 2.4 mg administration was 14.9%. The average weight of trial participants was 105.3 kg, and the average BMI was 37.9 kg/m².
Epe's discontinuation rate was relatively low compared to other obesity drugs such as Wegovy and Mounjaro. Epe recorded a permanent discontinuation rate due to serious adverse events of 0.66% in the domestic Phase 3 clinical trial. Wegovy had a serious adverse event incidence rate of 9.8% in the STEP-1 clinical trial, while for Mounjaro, the serious adverse event incidence rate in the 'SURMOUNT-1' clinical trial was 6.3% at 5 mg, 6.9% at 10 mg, and 5.1% at 15 mg by dosage. However, because the evaluation metrics and clinical designs differ, and it is not a direct comparative trial, it is difficult to definitively determine superiority between the drugs.
A Hanmi Pharmaceutical official stated, "In the domestic Phase 3 clinical trial for Epe, approximately 82% of all clinical participants had a BMI below 35 kg/m², which differs fundamentally in its starting point from Western studies centered on severe obesity with an average baseline BMI of about 38 kg/m²." The official added, "Patients with a BMI of 27 to 35 kg/m², commonly seen in Korea, made up the majority of the clinical trial. In this patient group, we confirmed an average weight loss of about 10%, good tolerability, and a low permanent discontinuation rate due to serious adverse events, so Epe can be called a 'treatment optimized for Koreans.'"
The official further added, "Hanmi Pharmaceutical will continue to accumulate clinical evidence obtained from domestic patients while supporting the overall treatment of patients by linking diet, exercise, medication, and lifestyle management through the digital solution app 'EpiDay' for obesity treatment patients, as well as providing health functional food support for supplementing insufficient nutrients." The official emphasized, "The prescription strategy for Epe is not about competing on a single weight loss figure, but about providing appropriate treatment options to patients and helping them maintain healthy weight loss in the long term."